Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint...
More...
More...